BioCentury on BioBusiness, Finance
Table: 2Q approvals
Related tables, figures and sidebars
Published on Monday, July 5, 2010
Selected
second quarter product approvals
|
Company
|
Approvals
|
|
Alexion
Pharmaceuticals Inc. (NASDAQ:ALXN)
|
Japan
approves Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria
(PNH)
|
|
Amgen Inc. (NASDAQ:AMGN)
|
FDA approves Prolia denosumab to treat osteoporosis
in postmenopausal women whoare at high risk of fractures or have failed or
are intolerant to other osteoporosis therapy; EC approves Prolia to treat
osteoporosis in postmenopausal women and to treat bone loss associated with
hormone ablation in men with prostate cancer at increased risk of fractures
|
|
BioAlliance
Pharma S.A. (Euronext:BIO)
|
FDA
approves Oravig miconazole to treat oropharyngeal candidiasis
|
|
Celgene
Corp. (NASDAQ:CELG)
|
Japan
approves Revlimid lenalidomide in combination with dexamethasone to treat
relapsed or refractory multiple myeloma (MM)
|
|
Cipher
Pharmaceuticals Inc. (TSX:DND)
|
FDA
approves Cip-tramadol ER to treat moderate to moderately severe chronic pain
|
|
Dendreon
Corp. (NASDAQ:DNDN)
|
FDA
approves Provenge sipuleucel-T to treat metastatic castrate-resistant
prostate cancer
|
|
Genmab
A/S (CSE:GEN)/
|
EC
grants conditional approval for Arzerra ofatumumab to treat chronic
lymphocytic
|
|
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)
|
leukemia (CLL) refractory to fludarabine and alemtuzumab
|
|
Genzyme
Corp. (NASDAQ:GENZ)
|
FDA
approves Lumizyme alglucosidase alfa to treat late (non-infantile) onset
Pompe's disease in patients who do not have evidence of cardiac hypertrophy
|
|
GlaxoSmithKline
plc (LSE:GSK; NYSE:GSK)
|
EC
conditionally approves Votrient pazopanib for first-line treatment of
advanced renal cell carcinoma (RCC)
|
|
GW
Pharmaceuticals plc (LSE:GWP)/
Bayer AG (Xetra:BAY)
|
U.K.
approves Sativex to treat spasticity due to multiple sclerosis (MS)
|
|
Hospira
Inc. (NYSE:HSP)
|
EC
approves Nivestim filgrastim to prevent febrile neutropenia and to reduce the
duration of chemotherapy-induced neutropenia
|
|
Inspire
Pharmaceuticals Inc. (NASDAQ:ISPH)/
Santen Pharmaceutical Co. Ltd. (Tokyo:4536; Osaka:4536)
|
Japan
approves Diquas diquafosol tetrasodium ophthalmic solution 3% to treat dry
eye
|
|
Johnson
& Johnson (NYSE:JNJ)
|
FDA
approves Pancreaze pancrelipase delayed-release capsules to treat pancreatic
exocrine insufficiency
|
|
Merck
& Co. Inc. (NYSE:MRK)
|
FDA
approves Dulera mometasone/formoterol inhalation aerosol to treat asthma
|
|
Novartis
AG (NYSE:NVS; SIX:NOVN)
|
FDA
grants accelerated approval to Tasigna nilotinib for first-line treatment of
Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in
chronic phase
|
319 words displayed of 1553 words total.
Get the Full Text...
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Broaden your Knowledge Base
The BioCentury Publications Package provides the essential coverage and analysis required by global biopharma decision makers.
Take advantage of our free trials and discover why BioCentury is the choice of biopharma professionals around the globe.
Free Trials Begin the Week Following Sign-up
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]